S67 Endocrine Therapy Resistance in Breast Cancer Patients: Pathogenesis and Its Conquest

Program: Symposia
Basic/Translational Session
Monday, April 4, 2016: 11:45 AM-1:15 PM
Room 157 (BCEC)
Chair:
Evan R Simpson, PhD, BSc, Prince Henry's Inst of Med Res, Clayton VIC, Australia

Nothing to Disclose: ERS
11:45 AM
Man-Ho Choi, Ph.D., Materials and Life Science Division, Korea Institute of Science and Technology, Seoul, South Korea
Nothing to Disclose: MHC
12:15 PM
Jennifer K Richer, PhD, Dept. of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO
Nothing to Disclose: JKR
12:30 PM
Kiyoshi Takagi, PhD, Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan
Nothing to Disclose: KT
12:45 PM
Steffi Oesterreich, PhD, Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA
Nothing to Disclose: SO
See more of: Symposia

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire